Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA
DA Haber, VE Velculescu - Cancer discovery, 2014 - AACR
The ability to study nonhematologic cancers through noninvasive sampling of blood is one
of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven …
of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven …
[HTML][HTML] Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
M Ignatiadis, SJ Dawson - Annals of oncology, 2014 - Elsevier
Next-generation sequencing studies have provided further evidence to support the notion
that cancer is a disease characterized by Darwinian evolution. Today, we often fail to …
that cancer is a disease characterized by Darwinian evolution. Today, we often fail to …
[HTML][HTML] Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
G Siravegna, A Bardelli - Genome biology, 2014 - Springer
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance |
Genome Biology Skip to main content SpringerLink Account Menu Find a journal Publish with …
Genome Biology Skip to main content SpringerLink Account Menu Find a journal Publish with …
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast …
C Palmieri, S Cleator, LS Kilburn, SB Kim… - Breast cancer research …, 2014 - Springer
Neoadjuvant endocrine therapy is an alternative to chemotherapy for women with oestrogen
receptor (ER)-positive early breast cancer (BC). We aimed to assess feasibility of recruiting …
receptor (ER)-positive early breast cancer (BC). We aimed to assess feasibility of recruiting …
[HTML][HTML] An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
A Sueta, Y Yamamoto, M Yamamoto-Ibusuki… - PLoS …, 2014 - journals.plos.org
The phosphoinositide-3-kinase (PI3K) pathway is commonly deregulated in breast cancer
through several mechanisms, including PIK3CA mutation and loss of phosphatase and …
through several mechanisms, including PIK3CA mutation and loss of phosphatase and …
Minimal residual disease in breast cancer: in blood veritas
G Siravegna, A Bardelli - Clinical Cancer Research, 2014 - AACR
A blood-based molecular test might direct recommendations for systemic therapies in
patients with early-stage breast cancer undergoing surgery with curative intent. A new study …
patients with early-stage breast cancer undergoing surgery with curative intent. A new study …
[PDF][PDF] Changing the paradigm: circulating tumor DNA as a 'liquid biopsy'for clinical biomarker assessments
TR Wilson, MR Lackner - Clinical Investigation, 2014 - gmo-qpcr-analysis.com
Clinical development of targeted anticancer therapies often involves interrogation of key
driver alterations through diagnostic assessment of tumor DNA. However, predictive …
driver alterations through diagnostic assessment of tumor DNA. However, predictive …
Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
I Prieto-Remon, ML Antelo-Caamano… - Recent Patents on …, 2014 - ingentaconnect.com
The prevalence of cancer in our days remains at high level all over the world. Implementing
and improving tools for better diagnostics and prognostics is a very active field of research …
and improving tools for better diagnostics and prognostics is a very active field of research …